Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Biora Therapeutics Receives Approval for First-in-Human Trial of BioJet™ Oral Biologic ...

4 November 2026 · By · Wire by Fusion42

Published

4 November 2026

Topic

opportunities

◆ Sectors

Drug Discovery

◆ Geography

United States

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 4 November 2026 · Fusion42 review

Biora Therapeutics has received regulatory approval to begin the first-in-human clinical trial for its BioJet™ oral biologic delivery capsule, marking a significant step in oral biologic drug delivery development.

This Wire brief sits within Fusion42's coverage of Drug Discovery.

◆ ◆ The Wire takeaway

You need to prepare for a shift in biologic drug delivery as oral options move toward clinical validation. That path opening changes the competitive and development priorities for drug delivery startups focused on biologics.

◆ Coverage

1 source · 4 Nov 2026

◆ Related on Wire

◆ Topics

Drug Discoveryclinical-trialoral-biologicsregulatory-approvaldrug-delivery